

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios

International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

* Review: Influencing the Wnt Signaling Pathway in Multiple Myeloma. Y. KIM, G. REIFENBERGER, D. LU, T. ENDO, D.A. CARSON, S.-M. GAST, K. MESCHENMOSER, M. NOWAK, I.G.H. SCHMIDT-WOLF (<i>Bonn; Duesseldorf, Germany; La Jolla, CA, USA; Sapporo, Hokkaido, Japan</i>)	725
Expression of the Vascular Endothelial Growth Factor (<i>VEGF</i>) Gene in Epithelial Ovarian Cancer: An Approach to Anti-VEGF Therapy. K. HATA, Y. WATANABE, H. NAKAI, T. HATA, H. HOSHIAI (<i>Takamastu; Osaka-Sayama; Kagawa, Japan</i>)	731
Forsen Psychological Risk Inventory for Breast Cancer Patients: A Prospective Case–Control Study with Special Reference to the Use of Psychiatric Medications. M. ESKELINEN, P. OLLONEN (<i>Kuopio, Finland</i>)	739
Significant Association of Caveolin-1 (<i>CAVI</i>) Genotypes with Prostate Cancer Susceptibility in Taiwan. H.-C. WU, C.-H. CHANG, Y.-A. TSOU, C.-W. TSAI, C.-C. LIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	745
* Reviews (pages 639, 649, 725)	

* Review: The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New Options. K.N. SYRIGOS, M.W. SAIF, E.M. KARAPANAGIOTOU, G. OIKONOMOPOULOS, F. DE MARINIS (Athens, Greece; New Haven, CT; New York, NY, USA; Rome, Italy).....	649
Pediatric Neuro-oncology in Small Centers – Quality Control of Network Support: The HIT-GBM Experience. J.E.A. WOLFF, P.H. DRIEVER, B. WOLFF, C.M. KRAMM, R.-D. KORTMANN, T. PIETSCH, S. RUTKOWSKI, A. GNEKOW (Houston, TX, USA; Berlin; Halle; Leipzig; Bonn; Hamburg; Augsburg, Germany)	661
Heterogeneity of Primary Site Biopsies in Head and Neck Squamous Cell Carcinoma. S. MOERTEL, H. ACKERMANN, M. BAGHI, A. ECKARDT, J. WAGENBLAST, T. STÖVER, M. HAMBEK (Frankfurt am Main, Germany).....	665
Pre-menopausal Hormone-responsive Breast Cancer with Extensive Axillary Nodes Involvement: Total Estrogen Blockade and Chemotherapy. F. RECCHIA, G. CANDELORO, S. NECOZIONE, G. DESIDERI, C.O.C. RECCHIA, J. PIAZZE, S. REA (Avezzano; Rome; L’Aquila, Italy)	671
Alcohol-dehydrogenase (ADH1B) Arg48His Polymorphism in Basque Country Patients with Oral and Laryngeal Cancer: Preliminary Study. X. MARICHALAR-MENDIA, A. ACHA-SAGREDO, M.J. RODRIGUEZ-TOJO, N. REY-BARJA, M. HERNANDO-RODRIGUEZ, J.I. AGUIRREGAVIRIA, J.M. AGUIRRE-URIZAR (Leioa; San Sebastian, Spain)	677
Gastric Cancer in a Pregnant Woman Presenting with Low Back Pain and Bilateral Erythematous Breast Hypertrophy Mimicking Primary Inflammatory Breast Carcinoma. V.D. MANDATO, D. PIRILLO, M.C. GELLI, M. CAVINA, G.B. LA SALA (Reggio Emilia, Italy)	681
Clinical Application of Determining Serum AFP-IgM Complexes for Diagnosis of Small Hepatocellular Carcinoma. J. JIANG, C. WU, Y. SHEN, B. XU, X. ZHENG, X. LI, N. XU (Changzhou; Suzhou, PR China; Lund, Sweden).....	687
Axillary Node Sampling in Conjunction with Sentinel Node Biopsy in Patients with Breast Cancer. A Prospective Preliminary Study. F. LUMACHI, L. NORBERTO, S. ZANELLA, F. MARINO, S.M.M. BASSO, U. BASSO, A. BRUNELLO, A. FASSINA (Padova; Pordenone, Italy)	693
Prognostic Significance of Peripheral Blood CD8 ^{high} CD57 ⁺ Lymphocytes in Bladder Carcinoma Patients After Intravesical IL-2. D. CHARACIEJUS, V. PAŠUKONIENĖ, J.J.L. JACOBS, R. EIDUKEVIČIUS, F. JANKEVIČIUS, N. DOBROVLSKIENĖ, M. MAURICAS, R.J. VAN MOORSELAAR, W. DEN OTTER (Vilnius, Lithuania; Amsterdam, Netherlands)	699
Effect of Genetic Polymorphisms Related to DNA Repair and the Xenobiotic Pathway on the Prognosis and Survival of Gastric Cancer Patients. T. TAHARA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, J. YONEMURA, T. ISHIZUKA, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H. FUJITA, Y. NAKAGAWA, M. NAGASAKA, M. IWATA, H. YAMADA, I. HIRATA, T. ARISAWA (Toyoake; Ishikawa, Japan)	705
Loss of Estrogen Receptor Beta Expression Correlates with Shorter Overall Survival and Lack of Clinical Response to Chemotherapy in Ovarian Cancer Patients. A. HALON, E. NOWAK-MARKWITZ, A. MACIEJCZYK, M. PUDELKO, T. GANSUKH, B. GYÖRFFY, P. DONIZY, D. MURAWA, R. MATKOWSKI, M. SPACZYNSKI, H. LAGE, P. SUROWIAK (Wroclaw; Poznan, Poland; Ulan Bator, Mongolia; Budapest, Hungary; Berlin, Germany)	711
Hemangiopericytoma/Solitary Fibrous Tumor of the Oral Cavity. F. ANGIERO, A. SIGNORE, S. BENEDECENTI (Milan; Genoa, Italy)	719

Mutations and Aberrant Transcriptions of <i>Stk11 (Lkb1)</i> Gene in Rat Liver Tumors. N. WAKABAYASHI, K. OKABE, M. HAYASHI, K. HONOKI, T. TSUJIUCHI (<i>Higashiosaka, Osaka; Kashihara, Nara, Japan</i>)	543
The Role of MAPK Pathway in Bone and Soft Tissue Tumors. K. SASAKI, T. HITORA, O. NAKAMURA, R. KONO, T. YAMAMOTO (<i>Kagawa, Japan</i>).....	549
Tissue Expression of Glycated Apolipoprotein B in Colorectal Adenoma and Cancer. R. REDDAVIDE, G. MISCIAGNA, M.G. CARUSO, M. NOTARNICOLA, R. ARMENTANO, M.L. CARUSO, M. PIRRELLI, A.M. VALENTINI (<i>Castellana Grotte, Italy</i>)	555
Late Residual γ -H2AX Foci in Murine Spinal Cord Might Facilitate Development of Response-modifying Strategies: A Research Hypothesis. N. ANDRATSCHKE, T. BLAU, S. SCHILL, C. NIEDER (<i>Munich; Cologne, Germany; Bodø; Tromsø, Norway</i>).....	561
Glutamate Receptors in Laryngeal Cancer Cells. A. STEPULAK, H. LUKSCH, O. UCKERMANN, M. SIFRINGER, W. RZESKI, K. POLBERG, K. KUPISZ, J. KLATKA, M. KIEŁBUS, A. GRABARSKA, J. MARZAHN, L. TURSKI, C. IKONOMIDOU (<i>Lublin, Poland; Dresden; Berlin, Germany; Weesp, Netherlands; Madison, WI, USA</i>)	565
Associations between Single Nucleotide Polymorphisms of <i>MMP2</i> , <i>VEGF</i> , and <i>HIF1A</i> Genes and the Risk of Developing Colorectal Cancer. M.-J. KANG, S.-A. JUNG, J.M. JUNG, S.-E. KIM, H.-K. JUNG, T.-H. KIM, K.-N. SHIM, S.Y. YI, K. YOO, I.H. MOON (<i>Seoul, South Korea</i>)	575
<i>Clinical Studies</i>	
Implementation of Molecular Intra-operative Assessment of Sentinel Lymph Node in Breast Cancer. A. KHADDAGE, S.-A. BERREMILA, F. FOREST, A. CLEMENSON, C. BOUTEILLE, P. SEFFERT, M. PEOC'H (<i>St. Etienne, France</i>)	585
Osseous Changes in Meningioma En Plaque. J. MATSCHKE, J. ADDO, C. BERNREUTHER, J. ZUSTIN (<i>Hamburg, Germany</i>)	591
Clinical Significance and Predictive Value of Prostaglandin E2 Receptors (EPR) 1 – 4 in Patients with Renal Cell Carcinoma. K. OHBA, Y. MIYATA, S.-I. WATANABE, T. HAYASHI, H. KANETAKE, S. KANDA, H. SAKAI (<i>Nagasaki, Japan</i>)	597
Vitamin D Supplement Doses and Serum 25-Hydroxyvitamin D in the Range Associated with Cancer Prevention. C.F. GARLAND, C.B. FRENCH, L.L. BAGGERLY, R.P. HEANEY (<i>La Jolla, CA; Omaha, NE, USA</i>)	607
Low Number of Detectable Circulating Tumor Cells in Non-metastatic Colon Cancer. M. THORSTEINSSON, G. SÖLETORMOS, P. JESS (<i>Roskilde; Hilleroed, Denmark</i>)	613
The Development of Bronchopleural Fistula in Lung Cancer Patients after Major Surgery: 31 Years of Experience with 19 Cases. H. URAMOTO, T. HANAGIRI (<i>Kitakyushu, Japan</i>)	619
A Phase I Study Evaluating the Effect of CDHP as a Component of S-1 on the Pharmacokinetics of 5-Fluorouracil. M.W. SAIF, L.S. ROSEN, K. SAITO, C. ZERGEBEL, L. RAVAGE-MASS, D.S. MENDELSON (<i>New York, NY; Santa Monica, CA; Princeton, NJ; Scottsdale, AZ, USA</i>)	625
Phase II Study of Combined Chemotherapy with Docetaxel, CDDP and 5-FU for Highly Advanced Esophageal Cancer. Y. OSAKA, M. SHINOHARA, S. HOSHINO, T. OGATA, Y. TAKAGI, A. TSUCHIDA, T. AOKI (<i>Tokyo, Japan</i>)	633
* Review: Prediction of Response in Cancer Immunotherapy. D. CHARACIEJUS, J.J.L. JACOBS, V. PAŠUKONIENĖ, N. KAZLAUSKAITĖ, V. DANILEVIČIŪTĖ, M. MAURICAS, W. DEN OTTER (<i>Vilnius, Lithuania; Amsterdam, Netherlands</i>)	639

A New Device for Rapid Isolation by Size and Characterization of Rare Circulating Tumor Cells. I. DESITTER, B.S. GUERROUAHEN, N. BENALI-FURET, J. WECHSLER, P.A. JÄNNE, Y. KUANG, M. YANAGITA, L. WANG, J.A. BERKOWITZ, R.J. DISTEL, Y.E. CAYRE (<i>Paris, France; Boston, MA, USA</i>)	427
The Prognostic Value of the Orphan Nuclear Receptor DAX-1 (NROB1) in Node-negative Breast Cancer. H. ZHANG, A. SLEWA, E. JANSSEN, I. SKALAND, Y. YU, E. GUDLAUGSSON, W. FENG, K. KJELLEVOLD, H. SØILAND, J.P.A. BAAK (<i>Stavanger; Bergen, Norway; Houston, TX, USA; Shanghai, PR China</i>)	443
Expression of Mucin-1, Galectin-1 and Galectin-3 in Human Leiomyosarcoma in Comparison to Leiomyoma and Myometrium. T. WEISSENBACHER, C. KUHN, D. MAYR, R. PAVLIK, K. FRIESE, C. SCHOLZ, U. JESCHKE, N. DITSCH, D. DIAN (<i>Munich, Germany</i>)	451
Oxidative Stress Reduces Na ⁺ /H ⁺ Exchange (NHE) Activity in a Biliary Epithelial Cancer Cell Line (Mz-Cha-1). C. ELSING, A. VOSS, T. HERRMANN, I. KAISER, C.A. HUEBNER, T. SCHLENKER (<i>Dorsten; Heidelberg; Idar-Oberstein; Jena, Germany</i>)	459
HAVcR-1 Reduces the Integrity of Human Endothelial Tight Junctions. T.A. MARTIN, G.M. HARRISON, M.D. MASON, W.G. JIANG (<i>Cardiff, UK</i>)	467
Natural Killer Cell Line YT Exerts Cytotoxicity Against CD86 ⁺ Myeloma Cells. U. HARNACK, H. JOHNEN, G. PECHER (<i>Berlin, Germany</i>)	475
Serum Derived from Zeranol-implanted ACI Rats Promotes the Growth of Human Breast Cancer Cells <i>In Vitro</i> . S. ZHONG, W.-P. YE, E. FENG, S.-H. LIN, J.-Y. LIU, J. LEONG, C. MA, Y.C. LIN (<i>Beijing, PR China; Columbus, OH, USA</i>)	481
The Effect of Normoxia and Hypoxia on a Prostate (PC-3) CD44/CD41 Cell Side Fraction. K.M. ANDERSON, P. GUINAN, M. RUBENSTEIN (<i>Chicago, IL, USA</i>)	487
Expression of Cancer Stem Cell Markers CD133 and CD44 in Locoregional Recurrence of Rectal Cancer. T. NAGATA, C. SAKAKURA, S. KOMIYAMA, A. MIYASHITA, M. NISHIO, Y. MURAYAMA, S. KOMATSU, A. SHIOZAKI, Y. KURIU, H. IKOMA, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, T. OCHIAI, Y. KOKUBA, T. SONOYAMA, E. OTSUJI (<i>Kyoto, Japan</i>)	495
Sonodynamically-induced Antitumor Effect of Mono-l-aspartyl Chlorin e6 (NPe6). N. YUMITA, Y. IWASE, K. NISHI, T. IKEDA, H. KOMATSU, T. FUKAI, K. ONODERA, H. NISHI, K. TAKEDA, S.-I. UMEMURA, K. OKUDAIRA, Y. MOMOSE (<i>Yokohama, Kanagawa; Sendai; Funabashi, Chiba, Japan</i>)	501
Hypoxia-inducible Adrenomedullin in Colorectal Cancer. M. UEMURA, H. YAMAMOTO, I. TAKEMASA, K. MIMORI, T. MIZUSHIMA, M. IKEDA, M. SEKIMOTO, Y. DOKI, M. MORI (<i>Osaka; Beppu, Japan</i>)....	507
Quantitative Structure–Cytotoxicity Relationship of Newly Synthesised Trihaloacetylazulenes Determined by a Semi-Empirical Molecular-Orbital Method (PM5). M. ISHIHARA, H. WAKABAYASHI, N. MOTOHASHI, H. SAKAGAMI (<i>Saitama; Tokyo, Japan</i>)	515
Reassessment of Estrogen Receptor Expression in Human Breast Cancer Cell Lines. C.H.J. FORD, M. AL-BADER, B. AL-AYADHI, I. FRANCIS (<i>Safat, Kuwait</i>)	521
Binding of Lactoferrin to IGBP1 Triggers Apoptosis in a Lung Adenocarcinoma Cell Line. D. LI, S. SAKASHITA, Y. MORISHITA, J. KANO, A. SHIBA, T. SATO, M. NOGUCHI (<i>Tsukuba, Ibaraki, Japan</i>)	529
Sustained Aberrant Localization of KL-6 Mucin and β-Catenin at the Invasion Front of Human Gastric Cancer Cells. Y. INAGAKI, W. TANG, H. XU, M. NAKATA, K.-I. MAFUNE, T. KONISHI, Y. SETO, N. KOKUDO (<i>Tokyo; Kanagawa, Japan</i>)	535